Breaking News Instant updates and real-time market news.

ENDP

Endo

$8.07

0.07 (0.88%)

06:29
05/13/19
05/13
06:29
05/13/19
06:29

Endo downgraded to Underweight from Neutral at JPMorgan

JPMorgan analyst Chris Schott downgraded Endo International to Underweight from Neutral with an unchanged price target of $9. With the company's collagenase clostridium histolyticum opportunity "likely remaining controversial" ahead of the product's launch in the second half of 2020, and opioid headlines continuing for the foreseeable future, the analyst sees few positive catalysts for the story this year and better opportunities elsewhere in his coverage.

ENDP Endo
$8.07

0.07 (0.88%)

03/05/19
LEER
03/05/19
DOWNGRADE
Target $10
LEER
Market Perform
Endo downgraded to Market Perform from Outperform at SVB Leerink
SVB Leerink analyst Ami Fadia downgraded Endo to Market Perform from Outperform due to a further step-down in the generics business in 2019, and the potential overhang from the opioid litigation. The analyst also lowered her price target on the shares to $10 from $13.
03/08/19
ADAM
03/08/19
NO CHANGE
Target $17
ADAM
Buy
Endo weakness a buying opportunity, says Canaccord
Canaccord analyst Dewey Steadman noted Endo shares have been under pressure due to concerns over the sustainability of the company's ex-injectables generics business and from competitors' news on the opioid litigation front. The analyst is looking for several upcoming catalysts for the company this year and continued execution on the company's key franchises, which he believes will lead to a second half of the year impact. Steadman reiterated his Buy rating and lowered his price target to $17 from $20 on Endo shares.
03/19/19
RHCO
03/19/19
INITIATION
Target $13
RHCO
Buy
Endo initiated with a Buy at SunTrust
SunTrust analyst Gregg Gilbert started Endo International with a Buy rating and $13 price target. Following the stock's underperformance in recent years, the analyst likes Endo's risk/reward profile despite its "debt leverage and opioid overhang." He believes investors are not currently paying much for collagenase clostridium histolyticum in cellulite, a "large market with limited options."
04/08/19
MZHO
04/08/19
NO CHANGE
MZHO
Mizuho sees upside risk to Endo, Mallinckrodt should Purdue go bankrupt
Mizuho analyst Irin Koffler believes a potential Purdue Pharma bankruptcy could benefit opioid defendants in that it could introduce "meaningful delays, lessen the body of evidence against other drug manufacturers, and potentially force the plaintiffs to rethink their original strategy and negotiating position (leading to lower settlements)." The risks are to the upside for Neutral-rated Endo (ENDP) and Mallinckrodt (MNK) as the opioid litigation progresses, Koffler tells investors in a research note.

TODAY'S FREE FLY STORIES

EL

Estee Lauder

$201.74

22.48 (12.54%)

07:37
08/20/19
08/20
07:37
08/20/19
07:37
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

VVUS

VIVUS

$3.46

-0.02 (-0.57%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Hot Stocks
VIVUS says study shows addition of Qsymia to LSG surgery improved weight loss »

VIVUS announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$125.55

0.73 (0.58%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 15

    Oct

TPIC

TPI Composites

$17.49

-0.2 (-1.13%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Upgrade
TPI Composites rating change  »

TPI Composites upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

PVTL

Pivotal Software

$13.85

-0.16 (-1.14%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

07:35
08/20/19
08/20
07:35
08/20/19
07:35
General news
Treasury Market Outlook: Treasuries are back in rally mode »

Treasury Market Outlook:…

DOW

Dow Inc.

$45.58

1.09 (2.45%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Hot Stocks
Dow Inc. to retrofit Louisiana cracker with FCDh technology to produce propylene »

Dow announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Oct

LULU

Lululemon

$178.63

0.83 (0.47%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
Lululemon analyst commentary  »

Lululemon earnings and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EVER

EverQuote

$22.18

0.88 (4.13%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
EverQuote analyst commentary  »

EverQuote price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITRI

Itron

$70.02

0.3 (0.43%)

07:33
08/20/19
08/20
07:33
08/20/19
07:33
Downgrade
Itron rating change  »

Itron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BIIB

Biogen

$235.61

4.05 (1.75%)

, NVTA

Invitae

$25.78

0.6 (2.38%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Biogen, Invitae announce availability of SMA STAT test »

Biogen (BIIB) and Invitae…

BIIB

Biogen

$235.61

4.05 (1.75%)

NVTA

Invitae

$25.78

0.6 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

MBRX

Moleculin Biotech

$1.15

0.07 (6.48%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Moleculin Biotech receives Emory University CTRC approval for WP1066 trial »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$74.86

1.6 (2.18%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Hot Stocks
Qualcomm, LGE enter new global patent license agreement »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

CRM

Salesforce

$143.66

-0.23 (-0.16%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

HAIN

Hain Celestial

$21.88

0.14 (0.64%)

07:28
08/20/19
08/20
07:28
08/20/19
07:28
Downgrade
Hain Celestial rating change  »

Hain Celestial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 15

    Sep

VNO

Vornado

$61.34

0.14 (0.23%)

07:26
08/20/19
08/20
07:26
08/20/19
07:26
Downgrade
Vornado rating change  »

Vornado downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MKC

McCormick

$168.53

-1.585 (-0.93%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
McCormick rating change  »

McCormick downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$54.67

2.28 (4.35%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
Las Vegas Sands rating change  »

Las Vegas Sands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$207.98

4.335 (2.13%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Home Depot analyst commentary  »

Home Depot Q2 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CSCO

Cisco

$48.50

1.54 (3.28%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Cisco analyst commentary  »

Cisco 'sum of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 10

    Oct

  • 13

    Nov

RGNX

Regenxbio

$37.50

0.27 (0.73%)

, ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Upgrade
Regenxbio, Adverum Biotechnologies rating change  »

Regenxbio upgraded to…

RGNX

Regenxbio

$37.50

0.27 (0.73%)

ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 11

    Sep

SILK

Silk Road Medical

$40.85

0.28 (0.69%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Initiation
Silk Road Medical initiated  »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENTX

Entera Bio

$2.30

-0.24 (-9.45%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Hot Stocks
Entera Bio to report results from Phase 2b study for oral PTH in September »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CPB

Campbell Soup

$43.17

0.53 (1.24%)

07:22
08/20/19
08/20
07:22
08/20/19
07:22
Upgrade
Campbell Soup rating change  »

Campbell Soup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 01

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.